



Clinical trial results:

Open-Label, Non-Randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer

Summary

EudraCT number	2013-000104-42
Trial protocol	DE
Global end of trial date	09 April 2014

Results information

Result version number	v1 (current)
This version publication date	09 April 2016
First version publication date	09 April 2016

Trial information

Trial identification

Sponsor protocol code	U31287-A-U201E
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Daiichi Sankyo Development Limited
Sponsor organisation address	Chiltern Place, Chalfont Park, Gerrards Cross, United Kingdom, SL9 0BG
Public contact	Clinical Trial Information, Daiichi Sankyo Development Limited, 44 1753 482800, info@dsd-eu.com
Scientific contact	Clinical Trial Information, Daiichi Sankyo Development Limited, 44 1753 482800, info@dsd-eu.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 January 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 April 2014
Global end of trial reached?	Yes
Global end of trial date	09 April 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To allow continuation of study treatment for subjects who have demonstrated clinical benefit (stable disease or better) at the time of study closure for U31287-A-U201.

Protection of trial subjects:

The study was conducted in compliance with ethical principles that have their origin in the Declarations of Helsinki the International Conference on Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and applicable regulatory requirement(s):

- USA FDA GCP guidelines;
- USA Code of Federal Regulations Title 21, parts 11, 50, 54, 56, and 312;
- EU Directive 2001/20/EC Implementation of good clinical practice in the conduct of clinical studies on medicinal products for human use;
- EU Directive 2005/28/EC: Laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products;
- Other applicable regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 November 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Romania: 2
Country: Number of subjects enrolled	Germany: 2
Worldwide total number of subjects	4
EEA total number of subjects	4

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects who demonstrated clinical benefit (SD or better) at the time of study closure for U31287-A-U201, continued study treatment as last received in U31287-A-U201.

Pre-assignment

Screening details:

The open-label treatment assigned to each subject continuing under this protocol corresponded to the subject's randomly assigned treatment received under protocol U31287-A-U201 with the exception of placebo.

Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

N/A

Arms

Are arms mutually exclusive?	Yes
Arm title	Erlotinib
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Erlotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Commercial supplies of erlotinib were used. Erlotinib 150 mg or 100 mg tablet was self-administered PO QD. On the day of patritumab administration, erlotinib was taken after the infusion of patritumab was completed. Erlotinib was to be taken 1 h before or at least 2 h after meals.

Arm title	Erlotinib + Patritumab
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Erlotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Commercial supplies of erlotinib were used. Erlotinib 150 mg or 100 mg tablet was self-administered PO QD. On the day of patritumab administration, erlotinib was taken after the infusion of patritumab was completed. Erlotinib was to be taken 1 h before or at least 2 h after meals.

Investigational medicinal product name	Patritumab
Investigational medicinal product code	U3-1287
Other name	AMG 888
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patritumab infusions were administered every 3 weeks. Patritumab was administered as a continuous

intravenous infusion over 60 minutes (\pm 10 minutes). Infusion times could be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.

Number of subjects in period 1	Erlotinib	Erlotinib + Patritumab
Started	2	2
Completed	0	0
Not completed	2	2
Progressive Disease	2	2

Baseline characteristics

Reporting groups

Reporting group title	Treatment period
-----------------------	------------------

Reporting group description: -

Reporting group values	Treatment period	Total	
Number of subjects	4	4	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	1	1	
From 65-84 years	3	3	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	3	3	
Male	1	1	

End points

End points reporting groups

Reporting group title	Erlotinib
Reporting group description: -	
Reporting group title	Erlotinib + Patritumab
Reporting group description: -	

Primary: Safety - Adverse Events

End point title	Safety - Adverse Events ^[1]
End point description:	

End point type	Primary
End point timeframe:	
Until up to 60 days after end of treatment	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of U31287-A-U201E was to allow continuation of study treatment for subjects who demonstrated clinical benefit (stable disease [SD] or better) at the time of study closure for U31287-A-U201. Safety data were collected but analysis was descriptive only due to small sample size.

End point values	Erlotinib	Erlotinib + Patritumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: Number of AEs	2	2		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs were reported from time of Informed Consent to the EOT visit assessment and up to 53 days after the last dose of U3-1287, or, if U3-1287 was discontinued earlier or if subject received erlotinib alone, up to 30 days after the last dose of erlotinib

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.0

Reporting groups

Reporting group title	Erlotinib
Reporting group description: -	
Reporting group title	Erlotinib + Patritumab
Reporting group description: -	

Serious adverse events	Erlotinib	Erlotinib + Patritumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Erlotinib	Erlotinib + Patritumab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 2 (100.00%)	2 / 2 (100.00%)	
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Abdominal pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Although 1 subject was assigned the patritumab erlotinib combo on U201, they were on erlotinib and placebo at end of U201 and therefore only received erlotinib on U201E.

Notes: